Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support

Bone Marrow Transplantation volume 25, pages 25–29 (2000)Cite this article

Abstract

Multiple myeloma (MM) is characterized by the expansion of tumor plasma cells in bone marrow (BM), but neoplastic cells have been consistently detected in peripheral blood (PB). Peripheral blood progenitor cell (PBPC) collections have been widely used to support high-dose therapy for MM patients. A flow cytometric technique has been used to detect plasma cells in PB and PBPC harvests. High CD38 expression identified these cells, and their nature was confirmed by the coexpression of specific antigens, such as CD138 and cytoplasmic immunoglobulins. Malignant plasma cell reinfusion could negatively affect response rate and survival, as demonstrated in other hematological malignancies. To address this issue, the relationship between the number of reinfused plasma cells, response to chemotherapy and event-free survival (EFS) have been analyzed. Sixty-four MM patients were treated with intensified chemotherapy at diagnosis. They were mobilized with cyclophosphamide and G-CSF, and then treated with melphalan 100 mg/m2 (MEL100) followed by PBPC support. A second course was given after 2 months, and a third to patients not in complete remission. There was no correlation between the number of reinfused plasma cells and response rate after this intensified chemotherapy: patients attaining complete remission received 3.6 × 106/kg CD38+ cells, while those with a partial or no response received 5.6 and 2.9 × 106/kg CD38+ cells. Similarly, there was no correlation between the number of reinfused plasma cells and EFS. Patients receiving less than 4.85 × 106/kg CD38+ cells experienced a median EFS of 34.2 months as opposed to 36.4 months for those receiving more than 4.85 × 106/kg CD38+ cells (P = 0.7). Recurrence of the disease is consistently observed in MM: our data suggest that in vivo residual tumor cells, rather than reinfused plasma cells are more likely to be responsible for relapse. Bone Marrow Transplantation (2000) 25, 25–29.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Boccadoro M, Pileri A . Diagnosis, prognosis, and standard treatment of multiple myeloma Hematol/Oncol Clin North Am 1997 11: 111–131

    Article  CAS  Google Scholar 

  2. Gianni AM, Tarella C, Bregni M et al. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma J Clin Oncol 1994 12: 503–509

    Article  CAS  PubMed  Google Scholar 

  3. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91–97

    Article  CAS  PubMed  Google Scholar 

  4. Bensinger W, Rowley S, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma J Clin Oncol 1996 14: 1447–1456

    Article  CAS  PubMed  Google Scholar 

  5. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997 89: 789–793

    CAS  PubMed  Google Scholar 

  6. Barlogie B, Jagannath S, Naucke S et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma Bone Marrow Transplant 1998 21: 1101–1107

    Article  CAS  PubMed  Google Scholar 

  7. Gianni AM, Siena S, Bregni M et al. Granulocyte—macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation Lancet 1989 8663: 580–584

    Article  Google Scholar 

  8. Siegel D, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma Blood 1999 93: 51–54

    CAS  PubMed  Google Scholar 

  9. Mariette X, Fermand JP, Brouet JC . Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy Bone Marrow Transplant 1994 14: 47–50

    CAS  PubMed  Google Scholar 

  10. Corradini P, Voena C, Astolfi M et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting Blood 1995 85: 1596–1602

    CAS  PubMed  Google Scholar 

  11. Gazitt Y, Tian E, Barlogie B et al . Differential mobilization of myeloma cells and normal hematopoietic stem cells inmultiple myeloma after treatment with cyclophosphamide andgranulocyte–macrophage colony-stimulating factor Blood 1996 87: 805–811

    CAS  PubMed  Google Scholar 

  12. Vescio RA, Han EJ, Schiller GJ et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts Bone Marrow Transplant 1996 18: 103–110

    CAS  PubMed  Google Scholar 

  13. Omedè P, Tarella C, Palumbo A et al. Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses Br J Haematol 1997 99: 685–691

    Article  PubMed  Google Scholar 

  14. Corradini P, Voena C, Tarella C et al. Molecular and clinical remission in multiple myeloma: the role of autologous and allogeneic transplantation of hematopoietic cells J Clin Oncol 1999 17: 208–215

    Article  CAS  PubMed  Google Scholar 

  15. Lemoli RM, Fortuna A, Motta MR et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells Blood 1996 87: 1625–1634

    CAS  PubMed  Google Scholar 

  16. Brenner MK, Rill DR, Krance RA et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation Lancet 1993 341: 85–86

    Article  CAS  PubMed  Google Scholar 

  17. Palumbo A, Triolo S, Argentino C et al. Melphalan at 100mg/m2 (MEL 100) with stem cell support is superior to standard treatment in multiple myeloma: a retrospective case-matched analysis Blood 1999 94: 1248–1253

    CAS  PubMed  Google Scholar 

  18. Terstappen LWMM, Johnsen S, Segers-Nolten IMJ et al. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry Blood 1990 76: 1739–1747

    CAS  PubMed  Google Scholar 

  19. Wijdenes J, Vooijs WC, Clement C et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1 Br J Haematol 1996 94: 318–323

    Article  CAS  PubMed  Google Scholar 

  20. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  21. Anderson KC, Andersen J, Soiffer R et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma Blood 1993 82: 2568–2576

    CAS  PubMed  Google Scholar 

  22. Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma Blood 1995 86: 390–397

    CAS  PubMed  Google Scholar 

  23. Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors Blood 1990 76: 1860–1866

    CAS  PubMed  Google Scholar 

  24. Harousseau JL, Attal M, Payen C et al. Bone marrow versus peripheral blood versus CD34+ progenitors as the source of stem cell for autologous in multiple myeloma Bone Marrow Transplant 1998 21: (Suppl. 1) 205 (Abstr. 714)

    Google Scholar 

  25. Rawstron AC, Owen RG, Davies F et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage Br J Haematol 1997 97: 46–55

    Article  CAS  PubMed  Google Scholar 

  26. Corradini P, Boccadoro M, Voena C et al. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cμ sequence in immunoglobulin (IgG)- and IgA secreting multiple myelomas J Exp Med 1993 178: 1091–1096

    Article  CAS  PubMed  Google Scholar 

  27. Tricot G, Gazitt Y, Leemhuis T et al. Collection, tumor contamination and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma Blood 1998 91: 4489–4495

    CAS  PubMed  Google Scholar 

  28. Bensinger WI . Should we purge? Bone Marrow Transplant 1998 21: 113–115

    Article  CAS  PubMed  Google Scholar 

  29. Massaia M, Borrione P, Battaglio S et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy Blood 1999 94: 673–683

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Associazione Italiana Ricerca Cancro (AIRC), Associazione Italiana Leucemie (AIL), and Ministero Universitá e Ricerca Scientifica e Tecnologica (MURST).

Author information

Authors and Affiliations

  1. Divisione Universitaria di Ematologia, Azienda Ospedaliera S Giovanni Battista di Torino, Torino, Italy

    M Boccadoro, P Omedé, A Dominietto, A Palumbo, S Bringhen, F Giaretta, B Ortolano, S Triolo & A Pileri

Authors
  1. M Boccadoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Omedé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Dominietto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Palumbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Bringhen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Giaretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Ortolano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Triolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Pileri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boccadoro, M., Omedé, P., Dominietto, A. et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant 25, 25–29 (2000). https://doi.org/10.1038/sj.bmt.1702085

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702085

Keywords

This article is cited by

Search

Advanced search

Quick links